Dr. Harith Rajagopalan is the Co-founder and CEO of Fractyl Health, a company he launched while serving as an Entrepreneur-in-Residence at General Catalyst Partners. Before founding Fractyl, Dr. Rajagopalan was an academic cardiologist and physician-scientist. He earned his B.S. in Chemistry from Stanford University and obtained both M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, he conducted award-winning research on intestinal cancers, with findings published in leading journals such as Nature and Science. Following medical school, he completed his residency in internal medicine and fellowship in clinical cardiology at Brigham and Women’s Hospital, along with a research fellowship at the Harvard Stem Cell Institute. Under Dr. Rajagopalan's leadership, Fractyl Health has developed innovative therapies targeting metabolic diseases. Notably, the company is advancing Rejuva®, a gene therapy platform designed for long-term remission of obesity and type 2 diabetes by altering metabolic hormone function in pancreatic islet cells. Rejuva is expected to enter first-in-human studies in the first half of 2025.